Search

everythinglearnresearchcommunity

for

Search:↓

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Tofacitinib may help treat nail dystrophy, especially when other treatments fail.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

The drug combination was safe and showed promise in treating advanced tumors.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

The microenvironment affects the behavior and survival of melanocytes with the GNAQ oncogene in melanoma.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.